PEDF-Fc融合蛋白的制備及其對肺腺癌A549細胞增殖和凋亡的影響
[Abstract]:Objective to construct and purify eukaryotic recombinant expression plasmid pc DNA3.4-PEDF-Fc, in HEK293F cells in order to obtain PEDF-Fc fusion protein with high expression quantity, high purity and biological activity. The effects of PEDF-Fc fusion protein alone and its combination with cisplatin on proliferation and apoptosis of lung adenocarcinoma cell line A549 were investigated in vitro. Methods PCR method was used to amplify the PEDF c DNA coding sequence. The amplified PEDF c DNA coding sequence was fused with the plasmid pc DNA3.4-Fc encoding the constant region gene of human immunoglobulin Ig G1Fc segment, and the pc DNA3.4-PEDF-Fc recombinant plasmid was constructed. The recombinant plasmid was transfected into HEK293F cells by liposome method. The supernatant of the cell culture supernatant was supernatant. The affinity medium Mabselect Su Re was used to purify the Fc fusion protein. The concentration of fusion protein was determined by BCA method in ultrafiltration centrifuge tube. SDS-PAGEG Western Blot was used to detect and identify the expressed protein. MTT assay was used to detect the proliferation inhibitory effect of different concentrations of PEDF-Fc fusion protein (2.5mL) on HUVECs and lung cancer A549 cells after 48 h intervention. The proliferation inhibitory effect of different concentrations of cisplatin (0.625 ~ 1.252.5 渭 g / mL) combined with PEDF-Fc fusion protein (10 渭 g / mL) on the proliferation of lung adenocarcinoma A549 cells was detected by MTT assay. The effects of different concentrations of PEDF-Fc fusion protein (10 ~ 40 渭 g / mL) on apoptosis of A549 cells were detected by flow cytometry. The effects of different concentrations of PEDF-Fc fusion protein (10 ~ 40 渭 g / mL) alone and combined with cisplatin (2 渭 g / mL) on apoptosis of A549 cells were investigated. Results double restriction endonuclease digestion and gene sequencing confirmed the successful construction of pc DNA3.4-PEDF-Fc recombinant plasmid. The eukaryotic expression vector was successfully constructed. The concentration of PEDF-Fc fusion protein was about 90 mg 路L ~ (-1) 3.65mg/m PEDF-Fc, which was confirmed by Western Blot method and 90 mg / L SDS-PAGE, and a high purity PEDF-Fc fusion protein was obtained. The molecular weight of the reductive PEDF-Fc fusion protein was about 75KDa. The results showed that PEDF-Fc fusion protein (2.5G / mL) could inhibit the proliferation of HUVECs, and the inhibitory effect increased with the increase of the concentration. When the concentration of PEDF-Fc fusion protein was more than 5 渭 g / mL, PEDF-Fc fusion protein could significantly inhibit the proliferation of A549 cells. The results showed that the A549 cells were treated with 10 渭 g / mL of DDP and 10 渭 g / mL of PEDF in a dose-dependent manner (P0.05). The proliferation inhibition of A549 cells in combination group was more obvious than that in DDP group alone (P0.05), and the flow rate showed that the apoptosis rate of HUVECs in PEDF-Fc intervention group (1040 渭 g / mL) was higher than that in control group (P0.05), and the apoptosis rate in high concentration intervention group was significantly higher than that in low concentration group (P0.05). Degree intervention group (P0.05); compared with PEDF-Fc or cisplatin alone group PEDF-Fc combined with cisplatin has a stronger apoptosis promotion effect on A549 cells (P0.05). Conclusion the eukaryotic expression vector of PEDF-Fc fusion protein was successfully constructed, and the PEDF-Fc fusion protein with high purity and biological activity was obtained, which laid a foundation for the study of the role of PEDF protein in the treatment of lung cancer. The results showed that PEDF-Fc fusion protein combined with low dose cisplatin could inhibit the proliferation and apoptosis of lung adenocarcinoma A549 cells more effectively than PEDF-Fc fusion protein or cisplatin alone. It suggests that the potential value of PEDF-Fc fusion protein combined with cisplatin in the treatment of lung cancer deserves further study.
【學位授予單位】:安徽醫(yī)科大學
【學位級別】:碩士
【學位授予年份】:2017
【分類號】:R734.2
【參考文獻】
相關(guān)期刊論文 前7條
1 Zhan-Wu Yu;Ying-Hua Ju;Cheng-Liang Yang;Han-Bing Yu;Quan Luo;Ye-Gang Ma;Yong-Yu Liu;;Antitumor effect of recombinant human endostatin combined with cisplatin on rats with transplanted Lewis lung cancer[J];Asian Pacific Journal of Tropical Medicine;2015年08期
2 婁志霞;束軍;金程;沈繼龍;;PEDF對人肺腺癌A549細胞增殖與凋亡的影響[J];安徽醫(yī)科大學學報;2014年10期
3 吳楨珍;查王健;陳菲菲;楊光宇;黃茂;;PEDF對低氧狀態(tài)下人支氣管上皮細胞表達VEGF的影響[J];南京醫(yī)科大學學報(自然科學版);2014年04期
4 劉正兵;束軍;;色素上皮衍生因子對非小細胞肺癌NCI-H460細胞增殖和凋亡的影響[J];安徽醫(yī)科大學學報;2013年06期
5 鄭金旭;許清;管淑紅;劉繼柱;宋萍;湯燕;吳立艷;;柴胡皂甙d干預(yù)肺纖維化VEGF/PEDF表達的實驗研究[J];天津醫(yī)藥;2012年08期
6 李瑞霞;陳海冰;;色素上皮衍生因子與氧化應(yīng)激[J];醫(yī)學綜述;2012年13期
7 鄭民;梁岳培;王洋;;非小細胞肺癌組織中VEGF、PEDF的表達變化及意義[J];山東醫(yī)藥;2011年18期
相關(guān)碩士學位論文 前1條
1 趙俊;胸腔積液中VEGF-A、VEGF-C、PEDF和CEA水平及其與中醫(yī)辨證分型的關(guān)系研究[D];南京中醫(yī)藥大學;2013年
,本文編號:2255737
本文鏈接:http://sikaile.net/yixuelunwen/zlx/2255737.html